Novartis AG (NYSE:NVS) [Trend Analysis] knocking active thrust in leading trading session, shares a decrease of -1.70% to 74.39 with around 3.74 Million shares have changed hands in this session. Novartis (NVS) revealed that new data suggesting that Cosentyx may modify the course of moderate-to-severe psoriasis leading to long-term, treatment-free skin clearance. The company said this is the first long-term data on psoriasis following treatment discontinuation.
Following one year of treatment with Cosentyx, patients were randomized to either continuous treatment or treatment cessation until relapse. Patients with continuous treatment maintained their high level of response. Among the patients that discontinued treatment, 21% of psoriasis patients maintained skin clearance for up to one year without treatment and 10% maintained skin clearance after two years without treatment.
“These results suggest that Cosentyx may go beyond simply treating symptoms and could actually modify the course of psoriasis, and highlights the need for further investigation into early intervention,” said Vas Narasimhan, Global Head, Drug Development and Chief Medical Officer, Novartis. The stock is going forward its fifty-two week low with 15.19% and lagging behind from its 52-week high price with -7.76%.
Similar, the positive performance for the quarter recorded as 7.41% and for the year was 4.64%, while the YTD performance remained at 5.85%. NVS has Average True Range for 14 days of 0.82.
Dana Incorporated (NYSE:DAN) [Trend Analysis] retains strong position in active trade, as shares scoring -4.75% to $18.26 in active trade session, while looking at the shares volume, around 2.18 Million shares have changed hands in this session. Dana Incorporated (DAN) reported that commencement of a cash tender offer for up to $75 million aggregate principal amount of its 5.375% Senior Notes due 2021, upon the terms and conditions set forth in the Offer to Purchase dated March 21, 2017.The Offer is slated to expire at 12:00 midnight, New York City time, at the end of April 17, 2017.
Holders of Notes who validly tender their Notes at or prior to 5:00 p.m., New York City time, on April 3, 2017 will be eligible to receive the “Total Consideration” of $1,040.31 per $1,000 principal amount of Notes tendered, which includes the “Early Tender Payment” of $30 per $1,000 of the Notes. Holders who validly tender their Notes after the Early Tender Time but at or before the Expiration Time will be eligible to receive the “Tender Offer Consideration” which is equal to the “Total Consideration” minus the “Early Tender Payment.” The firm has institutional ownership of 99.70%, while insider ownership included 0.40%. DAN attains analyst recommendation of 2.60 with week’s performance of -5.68%. Investors looking further ahead will note that the Price to next year’s EPS is 15.69%.